Abstract
Tofacitinib (Xeljanz((R))) is the first Janus kinase (JAK) inhibitor approved at a dosage of 5mg twice daily (BID) in the EU and the USA for the treat......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
